What is LEGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.82B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LEGN?

P/E (TTM) is n/a and 52-week range is $16.24 to $37.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LEGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LEGN?

The company profile lists revenue (TTM) near $638M, net income (TTM) near $-4.59B, EPS (TTM) near $-0.25 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Legend Biotech Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Somerset, New Jersey, US, 194.5M shares outstanding, ISIN US52490G1022 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Legend Biotech Corp

$LEGN

Health Care · Biotechnology

IR Run Scenarios

$18.62

-0.48%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. The company is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Website

investors.legendbiotech.com/

IPO

2020-06-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)